Background: We evaluated the relationship between thyroid remnant size following thyroidectomy for differentiated thyroid carcinoma and surgical volume and specialisation by assessing pre-ablation radioiodine-131 (131I) thyroid bed uptake (TBU) scanning as a surrogate for residual thyroid tissue. Methods: We analysed data of 651 patients in our thyroid cancer database. Patients' data were included if the following criteria were met: (1) diagnosis of differentiated thyroid carcinoma, (2) total or near-total thyroidectomy, (3) pre-ablation 131I scan prior to radioiodine ablation (RAI), (4) no distant metastasis, and (5) >3,000 MBq ablative dose of 131I. 131I diagnostic whole-body scans and measurement of thyroglobulin levels were carried out 3-9 months after RAI. 305 patients were included in the final analysis. Results: Four endocrine, 19 otolaryngology and 25 general surgeons performed thyroidectomies with median pre-ablation 131I TBU values of 1.0, 1.8 and 2.9%, respectively (p = 0.0031). There was a statistically significant relationship between number of thyroidectomies performed and median pre-ablation 131I TBU values up to the optimal number of 11 operations beyond which there was no further significant difference between surgeons. There were differences in remnant size between endocrine and general surgeons (p = 0.001), otolaryngology and general surgeons (p = 0.023) but not between endocrine and otolaryngology surgeons (p = 0.167). Conclusion: Using the pre-ablation 131I uptake scan as a surrogate for thyroid remnant quantification following thyroidectomy demonstrates the relationship between the surgical volume and size of thyroid remnant. The study also demonstrated beneficial effects of specialisation with specialist surgeons achieving the smallest thyroid remnant.

Keywords:
Thyroid cancer, Surgeon volume, Thyroid remnant, Pre-ablation radioiodine scan, Surgical specialisation
1.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R: The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-330.
2.
Scott-Coombes D, Kinsman R, Walton P: The British Association of Endocrine and Thyroid Surgeons (BAETS) Third National Audit Report, 2009. ISBN1-903968-25-9.
3.
Stavrakis AI, Ituarte PHG, Ko CYK, Yeh MW: Surgeon volume as a predictor of outcomes in patient and outpatient endocrine surgery. Surgery 2007;142:887-899.
4.
Chen H, Wang TS, Yen TWF, Doffek K, Krzywda E, Schaefer S, Sippel RS, Wilson SD: Operative failures after parathyroidectomy for hypoparathyroidism: the influence of surgical volume. Ann Surg 2010;252:691-695.
5.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumber M, Sherman SI, Steward DL, Tuttle RM: American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
6.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
7.
Dralle H, Sekulla C, Haerting J, Timmermann W, Neumann H, Kruse E, Grond S, Muhlig HP, Richter C, Voss J, Thomusch O, Lippert H, Gastinger I, Brauckhoff M, Gimm O: Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surg 2004;136:1310-1322.
8.
Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lee Lucas F: Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-2127.
9.
Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T: The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg 2002;89:1008-1013.
10.
Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB: Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000;119:1126-1132.
11.
Chowdhury MM, Dagash H, Pierro A: A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg 2007;94:145-161.
12.
Gourin CG, Tufano RP, Forastiere AA, Koch WM, Pawlik TM, Bristow RE: Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg 2010;136:1191-1198.
13.
Mitchell J, Milas M, Barbosa G, Sutton J, Berber E, Siperstein A: Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery 2008;144:899-907.
14.
Leblanc G, Tabah R, Liberman M, Sampalis J, Younan R, How J: Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer. Surgery 2004;136:1275-1280.
15.
Hackshaw AK, Harmer C, Mallick U, Haq M, Franklyn J: 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrin Metab 2007;92:28-38.
16.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clarke P, Farnell K, McCready R, Smellie J, Franklyn J, John R, Nutting C, Newbold K, Lemon C, Gerrard G, Abdul-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A: Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012;366:1674-1685.
17.
Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012;366:1663-1673.
18.
Van Nostrand D, Aiken M, Atkins F, Moreau S, Garcia C, Acio E, Burman K, Wartofsky L: The utility of radioiodine scans prior to iodine-131 ablation in patients with well-differentiated thyroid cancer. Thyroid 2009;19:849-855.
© 2013 European Thyroid Association Published by S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.